Independent director of Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) Pharmaceutical (Shanghai) Co., Ltd
Prior approval opinions on matters related to the seventh meeting of the Fourth Board of directors
In accordance with the company law of the people’s Republic of China, the rules for independent directors of listed companies, the rules for listing shares on the science and Innovation Board of Shanghai Stock Exchange, the articles of association of Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) Pharmaceutical (Shanghai) Co., Ltd., the rules of procedure of the board of directors, the working system of independent directors and other relevant laws, regulations and normative documents, As an independent director of Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) Pharmaceutical (Shanghai) Co., Ltd. (hereinafter referred to as “the company”), on the basis of carefully reading relevant materials and fully verifying the actual situation, we conducted a prior verification on the following proposals before the deliberation of the board of directors and expressed our opinions in advance:
1、 Prior approval opinions on the proposal on renewing the employment of the company’s audit institution in 2022
After verification, we agree that Ernst & Young Huaming Certified Public Accountants (special general partnership) has the qualification to engage in securities related business, has the experience and ability to provide audit services for listed companies, and can provide corresponding services for the company. We agree to renew the appointment of Ernst & Young Huaming Certified Public Accountants (special general partnership) as the company’s audit institution in 2022. And agreed to submit the proposal to the seventh meeting of the Fourth Board of directors for deliberation.
(no text below)
